Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 16/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22976467 | 1.00 | CHRM4 (0.42) | CHRM4GRM4SMPD3ACACB | |
| SCHEMBL29653424 | 0.85 | PIM1 (0.50) | — | |
| SCHEMBL15093842 | 0.82 | NOTUM (0.50) | SMPD3ACACB | |
| SCHEMBL30897180 | 0.78 | CKS1B (0.50) | — | |
| SCHEMBL28944316 | 0.77 | ACACB (0.43) | CHRM4ACACB | |
| SCHEMBL22976542 | 0.77 | AURKA (0.37) | SMPD3 | |
| SCHEMBL28944317 | 0.77 | ACACB (0.43) | CHRM4ACACB | |
| SCHEMBL22976543 | 0.77 | AURKA (0.37) | SMPD3 | |
| SCHEMBL15873402 | 0.74 | MEN1 (0.40) | CHRM4 | |
| SCHEMBL15873401 | 0.74 | MEN1 (0.40) | CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4294797-A1 | CRYSTALLINE FORMS OF A SOMATOSTATIN MODULATOR | Crinetics Pharmaceuticals, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| US-11773076-B2 | Crystalline forms of a somatostatin modulator | Crinetics Pharmaceuticals, Inc. (US) | 2023-10-03 | — | — | US | disclosed |
| WO-2022177974-A1 | CRYSTALLINE FORMS OF A SOMATOSTATIN MODULATOR | Crinetics Pharmaceuticals, Inc. (US) | 2022-08-25 | — | — | WO | disclosed |
| EP-4013748-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20220144802-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2022-05-12 | — | — | US | disclosed |
| WO-2021030262-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20210047287-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144802-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | SSTR5, SSTR4, SSTR3 | CHRM4 712/4885GRM4 334/4885SMPD3 312/4885 |
| US-20210047287-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | SSTR5, SSTR4, SSTR3 | CHRM4 712/4885GRM4 334/4885SMPD3 312/4885 |
| US-11773076-B2 | Crystalline forms of a somatostatin modulator | SSTR5, SSTR3, SSTR4 | CHRM4 728/4885GRM4 1841/4885SMPD3 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.